SparingVision
Vision-Saving Treatments Based On Groundbreaking Science

SparingVision is a genetic pharmaceutical company that develops vision-saving medications based on cutting edge research. SparingVision is driving a step-change in how ocular disorders are treated, moving beyond single gene corrective therapies, according to its scientific founders' 20 years of world-leading ophthalmic research at the Paris Vision Institute. A pipeline of gene-independent therapies for rod-cone dystrophies is at the center of this. The lead products, SPVN06 and SPVN20, respectively, target the mid and late phases of retinitis pigmentosa (RP). Two million people worldwide suffer from RP, which is the most common inherited retinal condition. These novel drugs could be the foundation for a new class of sight-saving treatments that could be used to treat a wide range of retinal illnesses, regardless of hereditary aetiology.

The company is backed by a strong, internationally renowned team that aims to use genomic medicine to speed up the delivery of novel medicines to all ocular disease sufferers. 4BIO Capital, Advent France Biotechnology, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital, and Ysios Capital are among SparingVision's investors.

SparingVision's mission is to use gene therapy and genome editing to provide cutting-edge innovation to the discovery and development of eye illness drugs. A pipeline of mutation independent treatments for Genetic Retinal Diseases (IRD) like Retinitis Pigmentosa (RP), the major inherited cause of blindness that affects 2 million people globally, lies at the centre of this. All patients are not candidates for current monogenic therapy techniques. SparingVision believes that with their method, they can make a significant difference in many patients.

Bringing together a world-class team of professionals from across the international drug development spectrum with 20+ years of world-leading ophthalmic research, SparingVision has a unique understanding of retinal disease and is dedicated to providing patients with cutting-edge solutions.

Gene therapy involves inserting a gene, encoding a therapeutic protein into cells using a delivery vehicle known as a vector to replace the defective or missing mutant gene that causes the patient's ailment.

SparingVision's AAV-based gene therapy solutions, unlike traditional monogenic gene treatments that target a specific gene, act independently of the underlying gene mutation to repair physiological systems in the retina and maintain vision. SPVN06, SparingVision's main product, is a ground-breaking gene therapy strategy for inherited retinal diseases (IRDs). SPVN06 can reduce or stop cone photoreceptor degradation, which eventually leads to blindness. Retinitis Pigmentosa (RP), one of the most common inherited retinal diseases that affect two million people globally, is the major disease target for SPVN06.
As SPVN06 therapy is mutation agnostic, it may be able to address more than 70 identified RP genetic mutations. SPVN06 is a single subretinal injection that expresses unique neurotrophic factors.

SparingVision's second product, SPVN20, is a groundbreaking gene therapy product acquired through the Gamut Therapeutics acquisition. SPVN20's innovative mutation-agnostic strategy promises to restore visual acuity and color vision in patients with "dormant cones" in advanced and late-stage Retinitis Pigmentosa (RP), regardless of their genetic mutation.

Dormant cones are viable cones with reduced outer segments that no longer respond to light, causing the patients' light response to decrease and their ability to see become impaired. Because the phototransduction cascade (allowing normal vision) happens in the outer segment of the cones, these dormant cones are no longer capable of turning light into an electric signal, leaving patients with tunnel vision and eventually blindness.